Cerenome, Inc. (CNSY) stock
Close on Nov 13, 2026Market cap $7.21MP/E –Yield –
Cerenome, Inc. saw revenue fall 32.9% to $3.53M over the twelve months to Sep 30, 2026. Free cash flow was -$28.70M. At the latest close the market valued the company at $7.21M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $7.21M
- P/E ratio
- –
- Price to sales
- 2.04
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -397.95%
Fundamentals
- Revenue
- $3.53M
- Net income
- -$30.32M
- EPS, diluted
- -$7.25
- Free cash flow
- -$28.70M
- Book value per share
- -$0.12
- Diluted shares
- 8M
Trading
- Next earnings
- Mar 11, 2027 (estimated, after the close)
- Previous close
- $0.77
- Open
- $0.81
- Day's range
- $0.81 – $1.18
- Volume
- 8,134,058
- Average volume (20 days)
- 2,212,727
- Beta (5 years)
- 0.59
- 52-week range
- $0.43 – $18.89
- RSI (14 days)
- 37.4
- Volatility (1 year)
- 114.3%
- Relative volume
- 16.43×
- WACC
- 8.1%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | CNSY | S&P 500 | Difference | CNSY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -45.4% | -3.0% | −42.4 pts | ||
| 3 months | -74.3% | -2.8% | −71.5 pts | ||
| Year to date | -92.6% | +11.5% | −104.1 pts | ||
| 1 year | -92.7% | +13.5% | −106.2 pts | ||
| 3 years | -97.4% | +77.7% | −175.1 pts | -70.4% | +21.1% |
| 5 years | -97.8% | +72.6% | −170.4 pts | -53.3% | +11.5% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cerenome filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- News
- Results
- Results
About Cerenome
Pharmaceutical Preparations
Plus Therapeutics, Inc. is a United States healthcare company focused on the development and commercialization of precision diagnostics and targeted radiotherapeutics for central nervous system cancers. Its clinical-stage pipeline features targeted radiopharmaceuticals intended to deliver radiation therapy directly to tumors, along with diagnostic solutions such as the CNSide platform and test designed for cerebrospinal fluid tumor cell enumeration, immunocytochemistry, fluorescence in situ hybridization, and next-generation sequencing. The company serves the medical and oncology sectors, targeting patients suffering from difficult-to-treat central nervous system cancers and conditions including leptomeningeal metastases.
Company profile, executives and historyCerenome stock: common questions
What is Cerenome's stock price?
CNSY closed at $0.95 on Nov 13, 2026, up 23.32% on the day. Over the past 52 weeks it traded between $0.43 and $18.89.
What is Cerenome's market cap?
Cerenome was worth $7.21M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is CNSY's P/E ratio?
Cerenome lost money over fiscal 2025 (diluted EPS -$7.25), so it has no meaningful P/E ratio.
How much revenue does Cerenome make?
Cerenome reported revenue of $3.53M for the twelve months to Sep 30, 2026, down 32.9% from a year earlier.
Does Cerenome pay a dividend?
No. Cerenome has not paid a cash dividend over the last twelve months.
When does Cerenome report earnings next?
Cerenome is expected to report Q4 FY2026 results on Mar 11, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has CNSY stock performed over the past year?
Including dividends, CNSY returned -92.7% over the past year, against +13.5% for the S&P 500.
How many CNSY shares are sold short?
1M shares were sold short at the latest FINRA report, 11.61% of the float, or 14.9 days of average trading volume.
Who are Cerenome's competitors?
Companies most similar to Cerenome by business, industry and size include RNXT, AURX, LUCD, NMTC, TNON.
See a number that looks wrong?